These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 8099509

  • 21. Neuroleptic malignant syndrome or parkinsonism hyperpyrexia syndrome.
    Granner MA, Wooten GF.
    Semin Neurol; 1991 Sep; 11(3):228-35. PubMed ID: 1947485
    [Abstract] [Full Text] [Related]

  • 22. Tardive dyskinesia.
    Gerlach J.
    Dan Med Bull; 1979 Aug; 26(5):209-45. PubMed ID: 40756
    [No Abstract] [Full Text] [Related]

  • 23. Dopamine and the pathophysiology of dyskinesias induced by antipsychotic drugs.
    Baldessarini RJ, Tarsy D.
    Annu Rev Neurosci; 1980 Aug; 3():23-41. PubMed ID: 6106450
    [No Abstract] [Full Text] [Related]

  • 24. Antipsychotic drugs: current use and future prospects.
    Livingston M.
    Biomed Pharmacother; 1987 Aug; 41(1):34-6. PubMed ID: 2886160
    [Abstract] [Full Text] [Related]

  • 25. Is there a rationale for iron supplementation in the treatment of akathisia? A review of the evidence.
    Gold R, Lenox RH.
    J Clin Psychiatry; 1995 Oct; 56(10):476-83. PubMed ID: 7559375
    [Abstract] [Full Text] [Related]

  • 26. Adaptive changes in brain dopamine function as a result of neuroleptic treatment.
    Jenner P, Marsden CD.
    Adv Neurol; 1988 Oct; 49():417-31. PubMed ID: 2894127
    [No Abstract] [Full Text] [Related]

  • 27. Neuroleptic malignant syndrome.
    Gratz S, Simpson G.
    Br J Psychiatry; 1990 Oct; 157():617-8. PubMed ID: 1983391
    [No Abstract] [Full Text] [Related]

  • 28. Neuroleptic malignant syndrome.
    Levenson JL.
    Am J Psychiatry; 1985 Oct; 142(10):1137-45. PubMed ID: 2863986
    [Abstract] [Full Text] [Related]

  • 29. Legal aspects of neuroleptic-induced movement disorders.
    Wettstein RM.
    Leg Med; 1985 Oct; ():117-79. PubMed ID: 2872562
    [No Abstract] [Full Text] [Related]

  • 30. [Rhabdomyolysis in neuroleptic therapy: an abortive malignant neuroleptic syndrome?].
    Peschel O, Kurtz G, Müller-Felber W, Modell S.
    Nervenarzt; 1994 Oct; 65(10):718-21. PubMed ID: 7808573
    [Abstract] [Full Text] [Related]

  • 31. [Physiopathology and curative treatment of tardive dyskinesia].
    Wolf MA, Gautier J.
    Encephale; 1987 Oct; 13(5):301-8. PubMed ID: 2892663
    [Abstract] [Full Text] [Related]

  • 32. Parallels between neuroleptic effects and lethargic encephalitis: the production of dyskinesias and cognitive disorders.
    Breggin PR.
    Brain Cogn; 1993 Sep; 23(1):8-27. PubMed ID: 8105824
    [Abstract] [Full Text] [Related]

  • 33. [Neuroleptic malignant syndrome (dopamine-dependent malignant hyperthermia). 4 different cases].
    Truong DD, Sczesni B, Fahn S, Gross J, Donovan K, van Bakel A, Wiley MK.
    Nervenarzt; 1988 Feb; 59(2):103-9. PubMed ID: 2896306
    [No Abstract] [Full Text] [Related]

  • 34. Neurologic complications of drugs. Tardive dyskinesias, neuroleptic malignant syndrome, and cocaine-related syndromes.
    Rodnitzky RL, Keyser DL.
    Psychiatr Clin North Am; 1992 Jun; 15(2):491-510. PubMed ID: 1351285
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Tardive dyskinesia. Pathophysiological mechanisms and clinical trials.
    Gerlach J.
    Encephale; 1988 Sep; 14 Spec No():227-32. PubMed ID: 2905651
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.